These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10219840)

  • 21. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function.
    Orlando R; Piccoli P; De Martin S; Padrini R; Floreani M; Palatini P
    Clin Pharmacol Ther; 2004 Jan; 75(1):80-8. PubMed ID: 14749694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoethylglycinexylidide formation in compensated cirrhosis: correlation with Child-Pugh score.
    Testa R; Borzone S; Campo N; Alvarez S; Caglieris S; Arzani L; Risso D; Lantieri PB; Celle G
    Transplant Proc; 1994 Dec; 26(6):3624-5. PubMed ID: 7998297
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic value of the monoethylglycinexylidide test in pediatric liver transplant candidates.
    Burdelski M; Schütz E; Nolte-Buchholtz S; Armstrong VW; Oellerich M
    Ther Drug Monit; 1996 Aug; 18(4):378-82. PubMed ID: 8857554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis.
    Shiffman ML; Luketic VA; Sanyal AJ; Duckworth PF; Purdum PP; Contos MJ; Mills AS; Edinboro LE; Poklis A
    Hepatology; 1994 Apr; 19(4):933-40. PubMed ID: 8138268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoethylglycinexylidide production as a measure in predicting hepatic histology.
    Forte G; Rocco P; Costanzo A; Grimaldi E; Rossi R; Bottiglieri ME; Biceglia O; Zampella G
    Ital J Gastroenterol; 1994 May; 26(4):159-62. PubMed ID: 7949258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects.
    Reichel C; Nacke A; Sudhop T; Wienkoop G; Lüers C; Hahn C; Pohl C; Spengler U; Sauerbruch T
    Hepatology; 1997 Jun; 25(6):1323-7. PubMed ID: 9185746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of an extended monoethylglycinexylidide formation test and other dynamic liver function tests in liver transplant donors.
    Zotz RB; von Schönfeld J; Erhard J; Breuer N; Lange R; Beste M; Goebell H; Eigler FW
    Transplantation; 1997 Feb; 63(4):538-41. PubMed ID: 9047147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of lidocaine metabolite (monoethylglycinexylidide) as a liver function test].
    Shimanuki K; Suzuki W; Sakurabayashi I; Kiyozaki H; Shinohara K; Soda K; Kai T; Satake M; Miyata M
    Nihon Shokakibyo Gakkai Zasshi; 1993 Jan; 90(1):33-40. PubMed ID: 8433534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease.
    Testa R; Caglieris S; Risso D; Arzani L; Campo N; Alvarez S; Giannini E; Lantieri PB; Celle G
    Am J Gastroenterol; 1997 Dec; 92(12):2268-73. PubMed ID: 9399768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lidocaine elimination and MEGX formation after oral lidocaine administration--a practicable test for assessment of quantitative liver function].
    Klinker H; Joeres R; Bomhard M; Keller F; Dorer J; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():52-5. PubMed ID: 7483715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
    Ferrara SD; Tedeschi L; Frison G; Orlando R; Mazzo M; Zordan R; Padrini R; Palatini P
    Eur J Clin Pharmacol; 1996; 50(4):305-10. PubMed ID: 8803524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of hepatic function in cystic fibrosis by lidocaine metabolism.
    Gremse DA; Sindel LJ; Hoff CJ; Wells DJ; Boerth RC
    J Pediatr Gastroenterol Nutr; 2001 Apr; 32(4):434-7. PubMed ID: 11396809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of liver function by the MEGX test in patients with schistosomiasis and cirrhosis.
    El Desoky ES; Ahmed AM; Nafeh MA; Ahmed HA; Schütz E; Armstrong VW; Oellerich M
    Clin Biochem; 1999 Apr; 32(3):207-12. PubMed ID: 10383082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of lidocaine and its active metabolite, monoethylglycinexylidide, after intravenous administration of lidocaine to awake and isoflurane-anesthetized cats.
    Thomasy SM; Pypendop BH; Ilkiw JE; Stanley SD
    Am J Vet Res; 2005 Jul; 66(7):1162-6. PubMed ID: 16111153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of one-year pretransplant survival in patients with cirrhosis.
    Oellerich M; Burdelski M; Lautz HU; Binder L; Pichlmayr R
    Hepatology; 1991 Dec; 14(6):1029-34. PubMed ID: 1959850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of liver disease and food on plasma MEGX concentrations.
    Pritchard-Davies R; Gross AS; Shenfield GM
    Br J Clin Pharmacol; 1994 Mar; 37(3):298-301. PubMed ID: 8198941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of lidocaine and its metabolite as a hepatic function marker in dogs.
    Pérez-Guillé BE; Villegas-Alvarez F; Toledo-López A; Jiménez-Bravo MA; González-Zamora JF; Carrasco-Portugal MC; Flores-Murrieta FJ; Soriano-Rosales RE
    Proc West Pharmacol Soc; 2011; 54():62-5. PubMed ID: 22423583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of lidocaine and its active metabolite monoethylglycinexylidide after a single intravenous administration in chickens (Gallus domesticus) anesthetized with isoflurane.
    Da Cunha AF; Messenger KM; Stout RW; Barker SA; Nevarez JG; Queiroz-Williams P; Tully TN
    J Vet Pharmacol Ther; 2012 Dec; 35(6):604-7. PubMed ID: 22212047
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
    Orlando R; Piccoli P; De Martin S; Padrini R; Palatini P
    Br J Clin Pharmacol; 2003 Jan; 55(1):86-93. PubMed ID: 12534644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formation of monoethylglycinexylidide (MEGX) in clinically healthy dogs.
    Neumann S; Frenz M; Streit F; Oellerich M
    Can J Vet Res; 2011 Oct; 75(4):317-20. PubMed ID: 22468031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.